company background image
EPIX logo

ESSA Pharma NasdaqCM:EPIX Stock Report

Last Price

US$8.56

Market Cap

US$378.7m

7D

-7.0%

1Y

178.8%

Updated

27 Mar, 2024

Data

Company Financials +

EPIX Stock Overview

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer.

EPIX fundamental analysis
Snowflake Score
Valuation1/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

ESSA Pharma Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for ESSA Pharma
Historical stock prices
Current Share PriceUS$8.56
52 Week HighUS$11.67
52 Week LowUS$2.56
Beta1.64
1 Month Change6.47%
3 Month Change20.73%
1 Year Change178.83%
3 Year Change-70.53%
5 Year Change161.77%
Change since IPO-90.31%

Recent News & Updates

We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

Feb 18
We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

Recent updates

We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

Feb 18
We're Not Very Worried About ESSA Pharma's (NASDAQ:EPIX) Cash Burn Rate

ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans

Aug 16
ESSA Pharma (NASDAQ:EPIX) Is In A Good Position To Deliver On Growth Plans

Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

Jan 25
Estimating The Fair Value Of ESSA Pharma Inc. (NASDAQ:EPIX)

We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely

Dec 15
We're Hopeful That ESSA Pharma (NASDAQ:EPIX) Will Use Its Cash Wisely

ESSA Pharma: Update Including Clinical Collaboration Agreement With Janssen

Feb 02

ESSA Pharma and Janssen to test combo treatments in prostate cancer setting

Jan 13

ESSA Pharma EPS beats by $0.02

Dec 15

Shareholder Returns

EPIXUS BiotechsUS Market
7D-7.0%0.9%0.4%
1Y178.8%10.3%28.8%

Return vs Industry: EPIX exceeded the US Biotechs industry which returned 9.6% over the past year.

Return vs Market: EPIX exceeded the US Market which returned 29.5% over the past year.

Price Volatility

Is EPIX's price volatile compared to industry and market?
EPIX volatility
EPIX Average Weekly Movement13.6%
Biotechs Industry Average Movement11.6%
Market Average Movement6.0%
10% most volatile stocks in US Market16.9%
10% least volatile stocks in US Market3.0%

Stable Share Price: EPIX's share price has been volatile over the past 3 months.

Volatility Over Time: EPIX's weekly volatility (14%) has been stable over the past year, but is still higher than 75% of US stocks.

About the Company

FoundedEmployeesCEOWebsite
200950David Parkinsonhttps://www.essapharma.com

ESSA Pharma Inc., a clinical stage pharmaceutical company, focuses the development of small molecule drugs for the treatment of prostate cancer. The company’s lead candidate EPI-7386, an androgen receptor based resistance mechanisms that develop in patients with castration-resistant prostate cancer and metastatic castration-resistant prostate cancer. It has collaboration agreements with Bayer Consumer Care AG; Janssen Research & Development, LLC; and Astellas Pharma Inc. ESSA Pharma Inc. was incorporated in 2009 and is headquartered in Vancouver, Canada.

ESSA Pharma Inc. Fundamentals Summary

How do ESSA Pharma's earnings and revenue compare to its market cap?
EPIX fundamental statistics
Market capUS$378.68m
Earnings (TTM)-US$25.80m
Revenue (TTM)n/a

0.0x

P/S Ratio

-14.7x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
EPIX income statement (TTM)
RevenueUS$0
Cost of RevenueUS$0
Gross ProfitUS$0
Other ExpensesUS$25.80m
Earnings-US$25.80m

Last Reported Earnings

Dec 31, 2023

Next Earnings Date

n/a

Earnings per share (EPS)-0.58
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did EPIX perform over the long term?

See historical performance and comparison
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.